title: FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors.
abstract: Psoriasis is a multifactorial skin disease affecting ~2% of world's population, causing a dramatic decrease in patients' quality of life and a significant increase in health-care expenses. Biological agents such as the anti-TNFα ones had an enormous impact in patients' therapy; however, a significant proportion of them do not respond well, an outcome attributed mainly to genetic factors. Recently, in a large European cohort of rheumatoid arthritis patients we have shown association with variation in the receptors that correspond to the Fc portion of the biological agents. As both diseases share common immunological fingerprints, we examined the hypothesis that they share common pharmacogenetic markers. Analysis of FCGR2A-H131R and FCGR3A-V158F polymorphisms in 100 psoriasis patients showed association only with respect to FCGR3A-V158F and response to etanercept (P=0.018). Interestingly, no association was found between FCGR2A-H131R and response to anti-TNFα therapy (P=0.882). This study suggests a role for FCGR3A-V158F polymorphism unique for psoriasis.
authors.affiliation: Laboratory of Genetics, Comparative and Evolutionary Biology, Department of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
authors.forename: E
authors.initials: E
authors.lastname: Mendrinou
authors.affiliation: 2nd Dermatology Department, Medical School, Papageorgiou Hospital, Aristotle University, Thessaloniki, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Patsatsi
authors.affiliation: Department of Dermatology, University General Hospital Larissa, University of Thessaly, Larissa, Greece.
authors.forename: E
authors.initials: E
authors.lastname: Zafiriou
authors.affiliation: Laboratory of Genetics, Comparative and Evolutionary Biology, Department of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
authors.forename: D
authors.initials: D
authors.lastname: Papadopoulou
authors.affiliation: Laboratory of Genetics, Comparative and Evolutionary Biology, Department of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
authors.forename: L
authors.initials: L
authors.lastname: Aggelou
authors.affiliation: Laboratory of Genetics, Comparative and Evolutionary Biology, Department of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
authors.forename: C
authors.initials: C
authors.lastname: Sarri
authors.affiliation: Laboratory of Genetics, Comparative and Evolutionary Biology, Department of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
authors.forename: Z
authors.initials: Z
authors.lastname: Mamuris
authors.affiliation: 2nd Dermatology Department, Medical School, Papageorgiou Hospital, Aristotle University, Thessaloniki, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Kyriakou
authors.affiliation: 2nd Dermatology Department, Medical School, Papageorgiou Hospital, Aristotle University, Thessaloniki, Greece.
authors.forename: D
authors.initials: D
authors.lastname: Sotiriadis
authors.affiliation: Department of Dermatology, University General Hospital Larissa, University of Thessaly, Larissa, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Roussaki-Schulze
authors.affiliation: Laboratory of Genetics, Comparative and Evolutionary Biology, Department of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
authors.forename: T
authors.initials: T
authors.lastname: Sarafidou
authors.affiliation: Laboratory of Genetics, Comparative and Evolutionary Biology, Department of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
authors.forename: Y
authors.initials: Y
authors.lastname: Vasilopoulos
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004351:Drug Resistance / Q000187:drug effects* / Q000235:genetics; D000068800:Etanercept / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005838:Genotype; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010597:Pharmacogenetics; D000071185:Pharmacogenomic Testing; D000071184:Pharmacogenomic Variants; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D017452:Receptors, IgG / Q000235:genetics*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
chemical_list: D000893:Anti-Inflammatory Agents; C496124:FCGR3A protein, human; D007141:Immunoglobulin Fc Fragments; D017452:Receptors, IgG; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept